What Challenges Exist in Targeting the Tumor Immune Microenvironment?
Despite advancements, several challenges exist in effectively targeting the TIME. Tumors exhibit significant heterogeneity, leading to diverse immune evasion mechanisms. Additionally, the plasticity of immune cells can lead to resistance against therapies. Identifying reliable biomarkers to predict patient response and developing personalized treatment plans remain critical hurdles in leveraging the TIME for cancer therapy.
